Galtier J, Basile G, Bouabdallah K. Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience". haematol [Internet]. 2020Sep.10 [cited 2026Jul.9];. Available from: https://haematologica.org/article/view/14282